EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • July 20th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 14, 2020 (the “Execution Date”), by and between NuGenerex Immuno-Oncology Inc., a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 20th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 14, 2020 (the “Execution Date”), is entered into by and between NUGENEREX IMMUNO-ONCOLOGY INC., a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
